Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02073968 · ClinicalTrials.gov registry record · Phase 2
PET-Adjusted Intensity Modulated Radiation Therapy and Combination Chemotherapy in Treating Patients With Stage II-IV Non-small Cell Lung Cancer
A Phase 2 study, sponsored by Albert Einstein College of Medicine.
- Completed
- Registry status
- Phase 2
- Development phase
- 35
- Enrollment target
NCT02073968 is a Phase 2 study that has completed, run by Albert Einstein College of Medicine. The registered enrollment target is 35 participants.
The verdict
NCT02073968, a Phase 2 study, has completed, sponsored by Albert Einstein College of Medicine.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 35 participants
- Enrollment target
Study Summary
This phase II trial studies how well intensity modulated radiation therapy adjusted by positron emission tomography (PET) scanning together with combination chemotherapy works in treating patients with stage II-IV non-small cell lung cancer (NSCLC). Radiation therapy uses high energy x rays to kill tumor cells. In intensity-modulated radiotherapy, multiple beam angles and dozens of beam segments are used to deliver highly conformal radiation therapy. Drugs used in chemotherapy, such as carboplatin and paclitaxel, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing. Giving PET-adjusted IMRT together with combination chemotherapy may kill more tumor cells.
Interventions
- DRUG Carboplatin
- PROCEDURE Computed Tomography
- PROCEDURE Positron Emission Tomography
- DRUG Paclitaxel
- RADIATION Intensity-Modulated Radiation Therapy
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 35 participants |
| Start Date | 2013-07 |
| Est. Completion | 2020-11 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02073968
The ClinicalTrials.gov registry entry for NCT02073968 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 35 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Albert Einstein College of Medicine, which has 175 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 5 interventions - of which Carboplatin is the first listed.
NCT02073968 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02073968 about?
NCT02073968 is a clinical study titled "PET-Adjusted Intensity Modulated Radiation Therapy and Combination Chemotherapy in Treating Patients With Stage II-IV Non-small Cell Lung Cancer". This phase II trial studies how well intensity modulated radiation therapy adjusted by positron emission tomography (PET) scanning together with combination chemotherapy works in treating patients with stage II-IV non-small cell lung cancer (NSCLC). Radiation therapy uses high energy x rays to kill ...
What is the current status of trial NCT02073968?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 35 participants. The study started on 2013-07. Estimated completion is 2020-11.
What interventions are being tested in trial NCT02073968?
The interventions under investigation include: Carboplatin (DRUG), Computed Tomography (PROCEDURE), Positron Emission Tomography (PROCEDURE), Paclitaxel (DRUG), Intensity-Modulated Radiation Therapy (RADIATION).
Who is sponsoring clinical trial NCT02073968?
This trial is sponsored by Albert Einstein College of Medicine, which has 175 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.